Loading...
XCSE
BIOPOR
Market cap81mUSD
Dec 04, Last price  
1.15DKK
1D
-2.54%
1Q
-14.81%
Jan 2017
-45.24%
Name

Bioporto A/S

Chart & Performance

D1W1MN
XCSE:BIOPOR chart
P/E
—
P/S
14.35
EPS
—
Div Yield, %
—
Shrs. gr., 5y
9.69%
Rev. gr., 5y
6.36%
Revenues
36m
+17.07%
4,362,0005,554,0008,340,0008,340,00011,008,00013,802,00018,584,00017,858,00016,625,00018,706,00020,383,00020,720,00025,155,00026,016,00026,622,00023,204,00024,254,00028,969,00030,958,00036,243,000
Net income
-68m
L+21.15%
-15,712,000-16,985,000-15,246,000-14,264,000-16,078,000-14,300,000-14,906,000-14,700,000-20,623,000-12,926,000-10,732,000-22,800,000-32,243,000-38,048,000-69,642,000-61,562,000-57,113,000-75,923,000-56,328,000-68,243,000
CFO
-84m
L+50.72%
-13,881-13,456-14,129,000-13,717,000-13,286,000-13,379,000-13,606,000-15,280,000-16,640,000-16,138,000-16,574,000-19,660,000-29,399,000-38,009,000-60,164,000-35,616,000-64,577,000-52,485,000-55,456,000-83,583,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

BioPorto A/S, an in-vitro diagnostics company, provides biomarker tests and tools, and antibodies for clinicians and researchers in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. The company was incorporated in 1917 and is based in Hellerup, Denmark.
URL
https://bioporto.com/
IPO date
Jan 02, 1985
Employees
Domiciled in
DK
Incorporated in
DK

Valuation

Title
DKK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT